Roughly one out of four 340B disproportionate share (DSH) hospitals could lose their eligibility for 340B drug discounts due to COVID-19 pandemic-related changes in patient mix, an analysis of hospital Medicare cost reports for 2019 and 2020 shows. About one out of 10 current 340B sole community hospitals (SCHs) and rural referral centers (RRCs) also are at risk.
Modern Healthcare did the analysis and reported its findings online on July 12. It based its projection of the share of 340B hospitals vulnerable to expulsion on a sample of hospital cost reports.
Roughly one out of four 340B disproportionate share (DSH) hospitals could lose their eligibility for 340B drug discounts due to COVID-19 pandemic-related changes in patient mix, an analysis of hospital Medicare cost reports for 2019 and 2020 shows. About one out of 10 current 340B sole community hospitals (SCHs) and rural referral centers (RRCs) also are at risk.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
